BACKGROUND: Recent prospective studies have shown a strong inverse association between sex hormone-binding globulin (SHBG) concentrations and risk of clinical diabetes in white individuals. However, it remains unclear whether this relationship extends to other racial/ethnic populations. METHODS: We evaluated the association between baseline concentrations of SHBG and clinical diabetes risk in the Women's Health Initiative Observational Study. Over a median follow-up of 5.9 years, we identified 642 postmenopausal women who developed clinical diabetes (380 blacks, 157 Hispanics, 105 Asians) and 1286 matched controls (777 blacks, 307 Hispanics, 202 Asians). RESULTS: Higher concentrations of SHBG at baseline were associated with a significantly lower risk of clinical diabetes [relative risk (RR), 0.15; 95% CI, 0.09-0.26 for highest vs lowest quartile of SHBG, adjusted for BMI and known diabetes risk factors]. The associations remained consistent within ethnic groups [RR, 0.19 (95% CI, 0.10-0.38) for blacks; RR, 0.17 (95% CI, 0.05-0.57) for Hispanics; and 0.13 (95% CI, 0.03-0.48) for Asians]. Adjustment for potential confounders, such as total testosterone (RR, 0.11; 95% CI, 0.07-0.19) or HOMA-IR (RR, 0.26; 95% CI, 0.14-0.48) did not alter the RR substantially. In addition, SHBG concentrations were significantly associated with risk of clinical diabetes across categories of hormone therapy use (never users: RR(per SD) = 0.42, 95% CI, 0.34-0.51; past users: RR(per SD) = 0.53;, 95% CI, 0.37-0.77; current users: RR(per SD) = 0.57; 95% CI, 0.46-0.69; P-interaction = 0.10). CONCLUSIONS: In this prospective study of postmenopausal women, we observed a robust, inverse relationship between serum concentrations of SHBG and risk of clinical diabetes in American blacks, Hispanics, and Asians/Pacific Islanders. These associations appeared to be independent of sex hormone concentrations, adiposity, or insulin resistance.
BACKGROUND: Recent prospective studies have shown a strong inverse association between sex hormone-binding globulin (SHBG) concentrations and risk of clinical diabetes in white individuals. However, it remains unclear whether this relationship extends to other racial/ethnic populations. METHODS: We evaluated the association between baseline concentrations of SHBG and clinical diabetes risk in the Women's Health Initiative Observational Study. Over a median follow-up of 5.9 years, we identified 642 postmenopausal women who developed clinical diabetes (380 blacks, 157 Hispanics, 105 Asians) and 1286 matched controls (777 blacks, 307 Hispanics, 202 Asians). RESULTS: Higher concentrations of SHBG at baseline were associated with a significantly lower risk of clinical diabetes [relative risk (RR), 0.15; 95% CI, 0.09-0.26 for highest vs lowest quartile of SHBG, adjusted for BMI and known diabetes risk factors]. The associations remained consistent within ethnic groups [RR, 0.19 (95% CI, 0.10-0.38) for blacks; RR, 0.17 (95% CI, 0.05-0.57) for Hispanics; and 0.13 (95% CI, 0.03-0.48) for Asians]. Adjustment for potential confounders, such as total testosterone (RR, 0.11; 95% CI, 0.07-0.19) or HOMA-IR (RR, 0.26; 95% CI, 0.14-0.48) did not alter the RR substantially. In addition, SHBG concentrations were significantly associated with risk of clinical diabetes across categories of hormone therapy use (never users: RR(per SD) = 0.42, 95% CI, 0.34-0.51; past users: RR(per SD) = 0.53;, 95% CI, 0.37-0.77; current users: RR(per SD) = 0.57; 95% CI, 0.46-0.69; P-interaction = 0.10). CONCLUSIONS: In this prospective study of postmenopausal women, we observed a robust, inverse relationship between serum concentrations of SHBG and risk of clinical diabetes in American blacks, Hispanics, and Asians/Pacific Islanders. These associations appeared to be independent of sex hormone concentrations, adiposity, or insulin resistance.
Authors: Sabina Rinaldi; Annabelle Geay; Henri Déchaud; Carine Biessy; Anne Zeleniuch-Jacquotte; Arslan Akhmedkhanov; Roy E Shore; Elio Riboli; Paolo Toniolo; Rudolf Kaaks Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-10 Impact factor: 4.254
Authors: William Rosner; Daniel J Hryb; Scott M Kahn; Atif M Nakhla; Nicholas A Romas Journal: Mol Cell Endocrinol Date: 2009-08-19 Impact factor: 4.102
Authors: Rita Rastogi Kalyani; Manuel Franco; Adrian S Dobs; Pamela Ouyang; Dhananjay Vaidya; Alain Bertoni; Susan M Gapstur; Sherita Hill Golden Journal: J Clin Endocrinol Metab Date: 2009-09-29 Impact factor: 5.958
Authors: Yiqing Song; JoAnn E Manson; Lesley Tinker; Barbara V Howard; Lewis H Kuller; Lauren Nathan; Nader Rifai; Simin Liu Journal: Diabetes Care Date: 2007-04-27 Impact factor: 19.112
Authors: Eric L Ding; Yiqing Song; JoAnn E Manson; David J Hunter; Cathy C Lee; Nader Rifai; Julie E Buring; J Michael Gaziano; Simin Liu Journal: N Engl J Med Date: 2009-08-05 Impact factor: 91.245
Authors: Simin Liu; Lesley Tinker; Yiqing Song; Nader Rifai; Denise E Bonds; Nancy R Cook; Gerardo Heiss; Barbara V Howard; Gokhan S Hotamisligil; Frank B Hu; Lewis H Kuller; JoAnn E Manson Journal: Arch Intern Med Date: 2007 Aug 13-27
Authors: John R B Perry; Michael N Weedon; Claudia Langenberg; Anne U Jackson; Valeriya Lyssenko; Thomas Sparsø; Gudmar Thorleifsson; Harald Grallert; Luigi Ferrucci; Marcello Maggio; Giuseppe Paolisso; Mark Walker; Colin N A Palmer; Felicity Payne; Elizabeth Young; Christian Herder; Narisu Narisu; Mario A Morken; Lori L Bonnycastle; Katharine R Owen; Beverley Shields; Beatrice Knight; Amanda Bennett; Christopher J Groves; Aimo Ruokonen; Marjo Riitta Jarvelin; Ewan Pearson; Laura Pascoe; Ele Ferrannini; Stefan R Bornstein; Heather M Stringham; Laura J Scott; Johanna Kuusisto; Peter Nilsson; Malin Neptin; Anette P Gjesing; Charlotta Pisinger; Torsten Lauritzen; Annelli Sandbaek; Mike Sampson; Ele Zeggini; Cecilia M Lindgren; Valgerdur Steinthorsdottir; Unnur Thorsteinsdottir; Torben Hansen; Peter Schwarz; Thomas Illig; Markku Laakso; Kari Stefansson; Andrew D Morris; Leif Groop; Oluf Pedersen; Michael Boehnke; Inês Barroso; Nicholas J Wareham; Andrew T Hattersley; Mark I McCarthy; Timothy M Frayling Journal: Hum Mol Genet Date: 2009-11-18 Impact factor: 6.150
Authors: Tracy E Madsen; Xi Luo; Mengna Huang; Ki E Park; Marcia L Stefanick; JoAnn E Manson; Simin Liu Journal: Stroke Date: 2020-02-12 Impact factor: 7.914
Authors: Yan Song; Yen-Tsung Huang; Yiqing Song; Andrea L Hevener; Kelli K Ryckman; Lihong Qi; Erin S LeBlanc; Rasa Kazlauskaite; Kathleen M Brennan; Simin Liu Journal: Diabetologia Date: 2015-01-08 Impact factor: 10.122
Authors: Yan Song; Michele Cho; Kathleen M Brennan; Brian H Chen; Yiqing Song; JoAnn E Manson; Andrea L Hevener; Nai-Chieh Y You; Anthony W Butch; Simin Liu Journal: J Diabetes Date: 2017-08-25 Impact factor: 4.006
Authors: K J Mather; C Kim; C A Christophi; V R Aroda; W C Knowler; S E Edelstein; J C Florez; F Labrie; S E Kahn; R B Goldberg; E Barrett-Connor Journal: J Clin Endocrinol Metab Date: 2015-07-22 Impact factor: 5.958